Q32 Bio

QTTB

Market cap $85.6M

WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m.

The consensus price target hints at a 97.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Q32 Bio is now largely a single-asset story centered on Bempikibart in alopecia areata, with mid-2026 topline data as the key catalyst. Management sold ADX-097 to Akebia, which brings milestone and royalty payments as an extra while concentrating its efforts on Bempikibart's R&D. Bempikibart's prior data and ongoing OLE data suggest durable responses and possible remission. This keeps my long-term alopecia areata thesis alive for QTTB.

MGY, ESCA, and QTTB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 27, 2026.

DNN, CM, MGY, QTTB and FLXS have been added to the Zacks Rank #1 (Strong Buy) List on March 27, 2026.

Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

FIGS, QTTB and NESR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 19, 2026.

FIGS, QTTB, ORN, FIX and PIPR have been added to the Zacks Rank #1 (Strong Buy) List on March 19, 2026.

QTTB, DXPE and TTEC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 13th, 2026.

The mean of analysts' price targets for Q32 Bio (QTTB) points to a 103.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.